| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Early Detection of Cancer | 13 | 2023 | 73 | 4.080 |
Why?
|
| Lung Neoplasms | 22 | 2023 | 383 | 3.970 |
Why?
|
| Mass Screening | 14 | 2023 | 223 | 3.550 |
Why?
|
| Colorectal Neoplasms | 8 | 2023 | 208 | 2.820 |
Why?
|
| Decision Making | 5 | 2022 | 180 | 2.690 |
Why?
|
| Primary Health Care | 9 | 2022 | 178 | 2.080 |
Why?
|
| Electronic Health Records | 4 | 2020 | 118 | 1.490 |
Why?
|
| Internship and Residency | 5 | 2017 | 283 | 1.490 |
Why?
|
| Students, Medical | 3 | 2022 | 121 | 1.260 |
Why?
|
| Access to Information | 2 | 2019 | 12 | 1.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2017 | 325 | 1.170 |
Why?
|
| Attitude of Health Personnel | 4 | 2016 | 161 | 1.120 |
Why?
|
| Humans | 67 | 2023 | 28998 | 1.110 |
Why?
|
| Computer-Assisted Instruction | 4 | 2015 | 21 | 1.070 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 104 | 1.010 |
Why?
|
| Internal Medicine | 4 | 2017 | 44 | 0.950 |
Why?
|
| Nursing Staff | 1 | 2022 | 4 | 0.860 |
Why?
|
| Curriculum | 5 | 2022 | 196 | 0.850 |
Why?
|
| Patient Education as Topic | 6 | 2012 | 251 | 0.850 |
Why?
|
| Caregivers | 2 | 2020 | 94 | 0.830 |
Why?
|
| Clinical Clerkship | 1 | 2022 | 41 | 0.820 |
Why?
|
| Polymorphism, Genetic | 9 | 2007 | 196 | 0.820 |
Why?
|
| Internet | 5 | 2019 | 156 | 0.800 |
Why?
|
| Privacy | 1 | 2020 | 9 | 0.760 |
Why?
|
| Steam | 1 | 2020 | 1 | 0.740 |
Why?
|
| Fires | 1 | 2020 | 4 | 0.740 |
Why?
|
| Philosophy | 2 | 2020 | 2 | 0.730 |
Why?
|
| United States | 14 | 2020 | 3604 | 0.720 |
Why?
|
| Hospitals | 1 | 2020 | 89 | 0.720 |
Why?
|
| User-Computer Interface | 2 | 2019 | 34 | 0.690 |
Why?
|
| Middle Aged | 31 | 2021 | 10805 | 0.680 |
Why?
|
| Male | 39 | 2020 | 17767 | 0.670 |
Why?
|
| Vulnerable Populations | 1 | 2018 | 25 | 0.640 |
Why?
|
| Female | 38 | 2022 | 18112 | 0.640 |
Why?
|
| Information Dissemination | 2 | 2016 | 41 | 0.640 |
Why?
|
| Science | 1 | 2017 | 8 | 0.630 |
Why?
|
| False Positive Reactions | 1 | 2017 | 25 | 0.630 |
Why?
|
| Patient Preference | 2 | 2015 | 38 | 0.610 |
Why?
|
| Health Literacy | 2 | 2015 | 26 | 0.610 |
Why?
|
| Health Education | 2 | 2015 | 121 | 0.580 |
Why?
|
| Medical Oncology | 1 | 2017 | 70 | 0.580 |
Why?
|
| Laboratories | 1 | 2016 | 13 | 0.560 |
Why?
|
| Glutathione Transferase | 3 | 2007 | 18 | 0.550 |
Why?
|
| Adult | 26 | 2023 | 8391 | 0.540 |
Why?
|
| Historiography | 1 | 2015 | 1 | 0.540 |
Why?
|
| Mathematics | 1 | 2015 | 9 | 0.540 |
Why?
|
| Alcohol-Related Disorders | 1 | 2015 | 22 | 0.530 |
Why?
|
| Aged | 22 | 2021 | 9461 | 0.530 |
Why?
|
| Physicians | 1 | 2017 | 134 | 0.530 |
Why?
|
| Prejudice | 2 | 2013 | 45 | 0.490 |
Why?
|
| Qualitative Research | 3 | 2022 | 142 | 0.490 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 95 | 0.480 |
Why?
|
| Prostatic Neoplasms | 3 | 2014 | 441 | 0.470 |
Why?
|
| Isoenzymes | 2 | 2003 | 63 | 0.460 |
Why?
|
| Awareness | 1 | 2013 | 28 | 0.460 |
Why?
|
| Smoking | 8 | 2022 | 427 | 0.430 |
Why?
|
| Cataract | 1 | 2011 | 5 | 0.410 |
Why?
|
| Androstadienes | 1 | 2011 | 17 | 0.410 |
Why?
|
| Glaucoma | 1 | 2011 | 11 | 0.410 |
Why?
|
| Albuterol | 1 | 2011 | 40 | 0.410 |
Why?
|
| Smoking Cessation | 2 | 2023 | 118 | 0.390 |
Why?
|
| Bronchodilator Agents | 1 | 2011 | 82 | 0.390 |
Why?
|
| Colonoscopy | 2 | 2023 | 41 | 0.380 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2008 | 36 | 0.370 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2020 | 24 | 0.370 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 120 | 0.360 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 1353 | 0.350 |
Why?
|
| Telemedicine | 2 | 2020 | 73 | 0.340 |
Why?
|
| Drug Industry | 1 | 2008 | 14 | 0.330 |
Why?
|
| Multimedia | 2 | 2005 | 12 | 0.330 |
Why?
|
| Medically Uninsured | 1 | 2008 | 31 | 0.330 |
Why?
|
| Logistic Models | 7 | 2020 | 725 | 0.330 |
Why?
|
| Patient Participation | 2 | 2022 | 62 | 0.320 |
Why?
|
| Patient Compliance | 2 | 2007 | 208 | 0.320 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 52 | 0.320 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 666 | 0.320 |
Why?
|
| Retrospective Studies | 5 | 2020 | 3100 | 0.320 |
Why?
|
| Academic Medical Centers | 2 | 2022 | 150 | 0.320 |
Why?
|
| Schools, Medical | 2 | 2022 | 42 | 0.310 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2007 | 5 | 0.310 |
Why?
|
| Drug Therapy | 1 | 2007 | 16 | 0.310 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2007 | 14 | 0.310 |
Why?
|
| Feasibility Studies | 3 | 2019 | 262 | 0.300 |
Why?
|
| Health Expenditures | 1 | 2007 | 61 | 0.300 |
Why?
|
| Tablets | 2 | 2022 | 10 | 0.290 |
Why?
|
| History, 20th Century | 2 | 2017 | 68 | 0.290 |
Why?
|
| North Carolina | 7 | 2016 | 1422 | 0.290 |
Why?
|
| Pilot Projects | 6 | 2017 | 469 | 0.290 |
Why?
|
| Population Surveillance | 1 | 2007 | 119 | 0.280 |
Why?
|
| Risk Assessment | 4 | 2019 | 1300 | 0.280 |
Why?
|
| Case-Control Studies | 12 | 2011 | 855 | 0.270 |
Why?
|
| Aged, 80 and over | 13 | 2015 | 3712 | 0.270 |
Why?
|
| Risk Factors | 14 | 2021 | 3509 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 871 | 0.260 |
Why?
|
| Office Visits | 1 | 2005 | 71 | 0.250 |
Why?
|
| Time Factors | 6 | 2019 | 1997 | 0.240 |
Why?
|
| Government Programs | 1 | 2023 | 8 | 0.230 |
Why?
|
| Clinical Competence | 2 | 2016 | 307 | 0.230 |
Why?
|
| Tobacco Use Cessation | 1 | 2023 | 13 | 0.230 |
Why?
|
| Occult Blood | 2 | 2017 | 9 | 0.230 |
Why?
|
| Ambulatory Care Facilities | 3 | 2019 | 63 | 0.230 |
Why?
|
| Program Evaluation | 5 | 2015 | 175 | 0.210 |
Why?
|
| Interviews as Topic | 3 | 2016 | 249 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 142 | 0.210 |
Why?
|
| Depression | 2 | 2022 | 378 | 0.210 |
Why?
|
| Efficiency, Organizational | 2 | 2016 | 18 | 0.200 |
Why?
|
| Educational Measurement | 2 | 2017 | 111 | 0.200 |
Why?
|
| Focus Groups | 1 | 2022 | 103 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 1374 | 0.200 |
Why?
|
| Prospective Studies | 4 | 2022 | 2010 | 0.200 |
Why?
|
| Obesity | 3 | 2013 | 1062 | 0.200 |
Why?
|
| Blood Glucose | 2 | 2020 | 465 | 0.190 |
Why?
|
| Glutathione S-Transferase pi | 3 | 2007 | 6 | 0.190 |
Why?
|
| Research Design | 2 | 2017 | 285 | 0.190 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 237 | 0.190 |
Why?
|
| Odds Ratio | 5 | 2011 | 446 | 0.190 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 78 | 0.190 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 142 | 0.190 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 301 | 0.190 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2020 | 3 | 0.190 |
Why?
|
| Fibroins | 1 | 2020 | 5 | 0.190 |
Why?
|
| Knowledge | 1 | 2020 | 15 | 0.180 |
Why?
|
| Endocrinology | 1 | 2019 | 2 | 0.180 |
Why?
|
| Thermodynamics | 1 | 2020 | 45 | 0.180 |
Why?
|
| Monitoring, Ambulatory | 1 | 2019 | 8 | 0.180 |
Why?
|
| Temperature | 1 | 2020 | 55 | 0.180 |
Why?
|
| Influenza, Human | 1 | 2021 | 122 | 0.180 |
Why?
|
| Preventive Health Services | 1 | 2020 | 30 | 0.180 |
Why?
|
| European Continental Ancestry Group | 4 | 2011 | 1131 | 0.180 |
Why?
|
| History, 21st Century | 2 | 2020 | 48 | 0.180 |
Why?
|
| Risk | 2 | 2017 | 289 | 0.170 |
Why?
|
| Sex Factors | 4 | 2016 | 626 | 0.170 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 115 | 0.170 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 207 | 0.170 |
Why?
|
| Disclosure | 1 | 2018 | 36 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 175 | 0.160 |
Why?
|
| Electroencephalography | 2 | 2016 | 71 | 0.160 |
Why?
|
| Drugs, Generic | 2 | 2008 | 13 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2019 | 96 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 385 | 0.160 |
Why?
|
| Terminology as Topic | 1 | 2017 | 62 | 0.150 |
Why?
|
| Patient Selection | 1 | 2019 | 257 | 0.150 |
Why?
|
| Motor Cortex | 1 | 2016 | 12 | 0.150 |
Why?
|
| Locomotion | 1 | 2016 | 31 | 0.150 |
Why?
|
| Education, Medical | 1 | 2017 | 67 | 0.150 |
Why?
|
| Choline Kinase | 1 | 2016 | 1 | 0.140 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 18 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2004 | 836 | 0.140 |
Why?
|
| Drug Discovery | 1 | 2016 | 30 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2021 | 691 | 0.140 |
Why?
|
| Logic | 1 | 2015 | 2 | 0.140 |
Why?
|
| England | 1 | 2015 | 4 | 0.140 |
Why?
|
| Family Practice | 1 | 2015 | 46 | 0.130 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2015 | 9 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 162 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2006 | 92 | 0.130 |
Why?
|
| Alcoholism | 1 | 2015 | 94 | 0.130 |
Why?
|
| Health Surveys | 1 | 2015 | 191 | 0.130 |
Why?
|
| Communication | 1 | 2016 | 122 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 1007 | 0.120 |
Why?
|
| Prevalence | 1 | 2016 | 892 | 0.120 |
Why?
|
| Drug Hypersensitivity | 1 | 2013 | 8 | 0.120 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2013 | 13 | 0.120 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 243 | 0.120 |
Why?
|
| Peroxidase | 2 | 2004 | 33 | 0.120 |
Why?
|
| Semantic Differential | 1 | 2013 | 6 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 31 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 2013 | 36 | 0.110 |
Why?
|
| African Americans | 3 | 2011 | 1373 | 0.110 |
Why?
|
| Bacteremia | 1 | 2013 | 53 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 292 | 0.110 |
Why?
|
| Data Collection | 2 | 2020 | 163 | 0.110 |
Why?
|
| Social Marketing | 1 | 2012 | 14 | 0.110 |
Why?
|
| Digital Rectal Examination | 2 | 2009 | 10 | 0.100 |
Why?
|
| MP3-Player | 1 | 2011 | 2 | 0.100 |
Why?
|
| Genotype | 5 | 2007 | 735 | 0.100 |
Why?
|
| Incidence | 3 | 2011 | 1105 | 0.100 |
Why?
|
| Warfarin | 1 | 2011 | 30 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2011 | 85 | 0.100 |
Why?
|
| Urban Health Services | 1 | 2011 | 10 | 0.100 |
Why?
|
| Community Health Centers | 1 | 2011 | 13 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 284 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 246 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2012 | 107 | 0.100 |
Why?
|
| Program Development | 1 | 2011 | 85 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3094 | 0.100 |
Why?
|
| Research | 1 | 2011 | 72 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2011 | 331 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 222 | 0.090 |
Why?
|
| Health Promotion | 1 | 2012 | 220 | 0.090 |
Why?
|
| Marketing of Health Services | 1 | 2008 | 4 | 0.080 |
Why?
|
| Masculinity | 1 | 2008 | 3 | 0.080 |
Why?
|
| Drug Costs | 1 | 2008 | 42 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2006 | 436 | 0.080 |
Why?
|
| Medicaid | 1 | 2008 | 83 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 35 | 0.080 |
Why?
|
| Formularies as Topic | 1 | 2007 | 3 | 0.080 |
Why?
|
| Prescription Fees | 1 | 2007 | 6 | 0.080 |
Why?
|
| Cost Sharing | 1 | 2007 | 10 | 0.080 |
Why?
|
| Cost Control | 1 | 2007 | 17 | 0.080 |
Why?
|
| Drug Utilization | 1 | 2007 | 47 | 0.080 |
Why?
|
| Arsenic Poisoning | 1 | 2007 | 1 | 0.080 |
Why?
|
| Health Behavior | 1 | 2009 | 212 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2003 | 9 | 0.070 |
Why?
|
| Infant | 3 | 2016 | 967 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 172 | 0.070 |
Why?
|
| Prognosis | 2 | 2008 | 1362 | 0.070 |
Why?
|
| Iron, Dietary | 1 | 2005 | 11 | 0.070 |
Why?
|
| Calcium, Dietary | 1 | 2005 | 23 | 0.070 |
Why?
|
| Zinc | 1 | 2005 | 32 | 0.070 |
Why?
|
| Lung | 2 | 2023 | 233 | 0.070 |
Why?
|
| Microcomputers | 1 | 2005 | 4 | 0.070 |
Why?
|
| Attitude to Computers | 1 | 2005 | 7 | 0.070 |
Why?
|
| North America | 1 | 2005 | 33 | 0.060 |
Why?
|
| Australia | 1 | 2005 | 66 | 0.060 |
Why?
|
| Europe | 1 | 2005 | 77 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 2105 | 0.060 |
Why?
|
| Medical Records | 1 | 2005 | 68 | 0.060 |
Why?
|
| Superoxide Dismutase | 1 | 2004 | 47 | 0.060 |
Why?
|
| Health Services | 1 | 2005 | 35 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2005 | 66 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 206 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 159 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 636 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2005 | 134 | 0.060 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 2004 | 55 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2005 | 147 | 0.060 |
Why?
|
| DNA Helicases | 1 | 2003 | 5 | 0.060 |
Why?
|
| DNA Primers | 1 | 2003 | 87 | 0.060 |
Why?
|
| Models, Biological | 1 | 2005 | 372 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2003 | 23 | 0.060 |
Why?
|
| Serine | 1 | 2003 | 11 | 0.060 |
Why?
|
| Codon | 1 | 2003 | 7 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2003 | 23 | 0.060 |
Why?
|
| Arginine | 1 | 2003 | 17 | 0.060 |
Why?
|
| Point Mutation | 1 | 2002 | 23 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 462 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 142 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 784 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 34 | 0.050 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2002 | 1 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2002 | 5 | 0.050 |
Why?
|
| Proteins | 1 | 2003 | 140 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2003 | 172 | 0.050 |
Why?
|
| Silk | 1 | 2021 | 2 | 0.050 |
Why?
|
| Needles | 1 | 2021 | 28 | 0.050 |
Why?
|
| Food Supply | 1 | 2021 | 52 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2022 | 202 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 133 | 0.050 |
Why?
|
| Drug Storage | 1 | 2020 | 3 | 0.050 |
Why?
|
| Poliomyelitis | 1 | 2020 | 4 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 17 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2020 | 14 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2020 | 84 | 0.050 |
Why?
|
| Educational Status | 2 | 2012 | 162 | 0.050 |
Why?
|
| Adolescent | 4 | 2011 | 3248 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 55 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2015 | 595 | 0.040 |
Why?
|
| Social Environment | 1 | 2020 | 74 | 0.040 |
Why?
|
| Survival Rate | 3 | 2008 | 795 | 0.040 |
Why?
|
| Hospitalists | 1 | 1999 | 7 | 0.040 |
Why?
|
| Workload | 1 | 1999 | 38 | 0.040 |
Why?
|
| Animals | 2 | 2021 | 7296 | 0.040 |
Why?
|
| Patients | 1 | 2018 | 46 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 185 | 0.040 |
Why?
|
| Age Factors | 3 | 2008 | 1105 | 0.040 |
Why?
|
| Movement | 1 | 2016 | 40 | 0.040 |
Why?
|
| Child Development | 1 | 2016 | 35 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2009 | 1674 | 0.040 |
Why?
|
| Phosphorylcholine | 1 | 2016 | 5 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 11 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 9 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2016 | 77 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2015 | 32 | 0.030 |
Why?
|
| Rats | 1 | 2020 | 1604 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 199 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2016 | 178 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 140 | 0.030 |
Why?
|
| Mice | 1 | 2021 | 2368 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 33 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2015 | 72 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 116 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 641 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2015 | 182 | 0.030 |
Why?
|
| beta-Lactams | 1 | 2013 | 5 | 0.030 |
Why?
|
| Empirical Research | 1 | 2013 | 8 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2013 | 7 | 0.030 |
Why?
|
| Apoptosis | 1 | 2016 | 337 | 0.030 |
Why?
|
| Tetracycline | 1 | 2013 | 11 | 0.030 |
Why?
|
| Fluoroquinolones | 1 | 2013 | 10 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 353 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2013 | 15 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 680 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 573 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2004 | 225 | 0.030 |
Why?
|
| Culture | 1 | 2013 | 38 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2003 | 106 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 273 | 0.030 |
Why?
|
| Alleles | 2 | 2003 | 251 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2002 | 140 | 0.030 |
Why?
|
| Reference Values | 2 | 2002 | 224 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2011 | 5 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 16 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 169 | 0.020 |
Why?
|
| Mentors | 1 | 2011 | 29 | 0.020 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2012 | 84 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 546 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 724 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2011 | 120 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 231 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 61 | 0.020 |
Why?
|
| Attitude | 1 | 2008 | 37 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 26 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2008 | 18 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2008 | 126 | 0.020 |
Why?
|
| Arsenic | 1 | 2007 | 5 | 0.020 |
Why?
|
| Causality | 1 | 2007 | 37 | 0.020 |
Why?
|
| Water Supply | 1 | 2007 | 10 | 0.020 |
Why?
|
| India | 1 | 2007 | 61 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 272 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 281 | 0.020 |
Why?
|
| DNA Adducts | 1 | 2005 | 13 | 0.020 |
Why?
|
| Safety | 1 | 2005 | 72 | 0.020 |
Why?
|
| Algorithms | 1 | 2008 | 461 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 2398 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2008 | 1164 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2003 | 1 | 0.010 |
Why?
|
| Boston | 1 | 2003 | 16 | 0.010 |
Why?
|
| Genetic Code | 1 | 2003 | 2 | 0.010 |
Why?
|
| Massachusetts | 1 | 2003 | 28 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2002 | 53 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2003 | 122 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 150 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 212 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 185 | 0.010 |
Why?
|
| Child | 1 | 2008 | 2209 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 197 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 514 | 0.010 |
Why?
|
| Bed Occupancy | 1 | 1999 | 1 | 0.010 |
Why?
|
| Hospital Bed Capacity | 1 | 1999 | 5 | 0.010 |
Why?
|
| Benchmarking | 1 | 1999 | 25 | 0.010 |
Why?
|
| Forecasting | 1 | 1999 | 133 | 0.010 |
Why?
|
| Models, Statistical | 1 | 1999 | 160 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 1999 | 113 | 0.010 |
Why?
|